The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia.

Radioimmunotherapy of cancer with radiolabeled antibodies has shown promise. alpha-Particles are very attractive for cancer therapy, especially for isolated malignant cells, as is observed in leukemia, because of their high linear energy transfer and short effective path length. We evaluated an anti-CD25 [interleukin-2 receptor alpha (IL-2R alpha)] monoclonal antibody, 7G7/B6, armed with (211)At as a potential radioimmunotherapeutic agent for CD25-expressing leukemias and lymphomas. Therapeutic studies were done in severe combined immunodeficient/nonobese diabetic mice bearing the karpas299 leukemia and in nude mice bearing the SUDHL-1 lymphoma. The results from a pharmacokinetic study showed that the clearance of (211)At-7G7/B6 from the circulation was virtually identical to (125)I-7G7/B6. The biodistributions of (211)At-7G7/B6 and (125)I-7G7/B6 were also similar with the exception of a higher stomach uptake of radioactivity with (211)At-7G7/B6. Therapy using 15 microCi of (211)At-7G7/B6 prolonged survival of the karpas299 leukemia-bearing mice significantly when compared with untreated mice and mice treated with (211)At-11F11, a radiolabeled nonspecific control antibody (P < 0.01). All of the mice in the control and (211)At-11F11 groups died by day 46 whereas >70% of the mice in the (211)At-7G7/B6 group still survived at that time. In summary, (211)At-7G7/B6 could serve as an effective therapeutic agent for patients with CD25-expressing leukemias.

[1]  T. Waldmann,et al.  Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. , 2006, Blood.

[2]  Richard L Wahl,et al.  131I-tositumomab therapy as initial treatment for follicular lymphoma. , 2005, The New England journal of medicine.

[3]  T. Waldmann,et al.  Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. , 2005, Blood.

[4]  M. Zalutsky,et al.  Radioimmunotherapy with alpha-particle emitting radionuclides. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[5]  W. Wilson,et al.  Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. , 2004, Blood.

[6]  M. Brechbiel,et al.  Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.

[7]  T. Waldmann.  ABCs of Radioisotopes Used for Radioimmunotherapy: α- and β-Emitters , 2003 .

[8]  T. Waldmann,et al.  Immunotherapy: past, present and future , 2003, Nature Medicine.

[9]  T. Waldmann,et al.  Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[11]  Richard J Lee,et al.  Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. , 2002, Molecular cancer therapeutics.

[12]  T. Waldmann,et al.  Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. , 2002, Blood.

[13]  T. Waldmann,et al.  Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. , 2002, Cancer research.

[14]  D. Scheinberg,et al.  Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.

[15]  T. Waldmann,et al.  Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac. , 2001, Nuclear medicine and biology.

[16]  T. Waldmann,et al.  Advances in interleukin 2 receptor targeted treatment , 2000, Annals of the rheumatic diseases.

[17]  M. Kaminski,et al.  Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. , 2000, Blood.

[18]  J. Humm,et al.  Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.

[19]  T. Waldmann,et al.  Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. , 1998, Nuclear medicine and biology.

[20]  G L DeNardo,et al.  Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia , 1997, Cancer.

[21]  R. Levy,et al.  Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  T. Waldmann,et al.  Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. , 1995, Blood.

[23]  I. Bernstein,et al.  Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas , 1995, The Lancet.

[24]  H. Sakahara,et al.  Radioimmunoimaging of colon cancer xenografts with anti-Tn monoclonal antibody. , 1995, Nuclear medicine and biology.

[25]  T. Waldmann,et al.  The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia , 1993 .

[26]  C. Coleman,et al.  Alpha particle radio-immunotherapy: animal models and clinical prospects. , 1989, International journal of radiation oncology, biology, physics.

[27]  A. O’Brien,et al.  Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay , 1988, Journal of clinical microbiology.

[28]  C. Coleman,et al.  Radioimmunotherapy with alpha-particle-emitting immunoconjugates. , 1988, Science.

[29]  D. Nelson,et al.  A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. , 1985, Hybridoma.